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1. INTRODUCTION {#dom13698-sec-0001}
===============

The duration of type 2 diabetes is an important determinant of cardiovascular and renal outcomes.[1](#dom13698-bib-0001){ref-type="ref"}, [2](#dom13698-bib-0002){ref-type="ref"}, [3](#dom13698-bib-0003){ref-type="ref"}, [4](#dom13698-bib-0004){ref-type="ref"}, [5](#dom13698-bib-0005){ref-type="ref"} However, less is known about whether antihyperglycaemic agents exert a consistent benefit on these outcomes as duration of type 2 diabetes increases. LEADER (N = 9340) and SUSTAIN 6 (N = 3297) were large cardiovascular outcome trials in patients with type 2 diabetes that demonstrated the beneficial cardiovascular effects of liraglutide and semaglutide, respectively, vs placebo, in addition to standard of care treatment.[6](#dom13698-bib-0006){ref-type="ref"}, [7](#dom13698-bib-0007){ref-type="ref"} In this post hoc analysis, we evaluated the impact of diabetes duration on key cardiovascular and renal outcomes following treatment with these two glucagon‐like peptide‐1 (GLP‐1) analogues.

2. METHODS {#dom13698-sec-0002}
==========

The study designs, methods and statistical analyses have been described previously.[6](#dom13698-bib-0006){ref-type="ref"}, [7](#dom13698-bib-0007){ref-type="ref"} In both trials, the primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction (MI) and nonfatal stroke (major adverse cardiovascular events \[MACE\]). The key secondary endpoint (expanded MACE) also included coronary revascularization and hospitalization for unstable angina or heart failure. Renal outcomes were adjudicated and assessed as part of a prespecified secondary microvascular endpoint which included nephropathy events, defined as the new onset of macroalbuminuria, or doubling of serum creatinine level and an estimated glomerular filtration rate (eGFR) of at most 45 mL/min/1.73 m^2^, or the need for continuous renal‐replacement therapy, or death from renal disease.

We evaluated the efficacy of liraglutide and semaglutide for these endpoints by diabetes duration at baseline using the following sub‐groups: \<5 years, 5 to \<15 years, 15 to \<25 years and ≥25 years. Hazard ratios (HRs) were estimated using a Cox proportional hazards model with treatment and diabetes duration sub‐group as factors, and the interaction between both factors. Furthermore, for the SUSTAIN‐6 trial, the Cox proportional hazards model was stratified for factors used for randomization.[6](#dom13698-bib-0006){ref-type="ref"} An interaction *P* value less than 0.05 was deemed significant. No adjustment for multiplicity was performed. Analyses were repeated with adjustment for baseline covariates: age, antihyperglycaemic medication, geographic region, history of MI or stroke, renal function (eGFR), sex and smoking status. Sensitivity analyses were also performed with four sub‐groups based on quartiles of diabetes duration.

3. RESULTS {#dom13698-sec-0003}
==========

3.1. Baseline characteristics {#dom13698-sec-0004}
-----------------------------

In the LEADER trial, 15% (n = 1377), 50% (n = 4692), 27% (n = 2504) and 8% (n = 748) of patients had baseline diabetes duration of \<5, 5 to \<15, 15 to \<25 and ≥25 years, respectively; corresponding proportions in the SUSTAIN‐6 trial were 13% (n = 422), 48% (n = 1582), 30% (n = 977) and 10% (n = 316) for sub‐groups \<5 years, 5 to \<15 years, 15 to \<25 years and ≥25 years, respectively. Baseline characteristics of patients according to duration of diabetes are shown in Table [1](#dom13698-tbl-0001){ref-type="table"}A and B. Across the diabetes duration strata in the LEADER and SUSTAIN 6 trials, mean diabetes duration was 3 years in the \<5 years sub‐group, 10 years in the 5 to \<15 years sub‐group, 19 years in the 15 to \<25 years sub‐group and 31 years in the \>25 years sub‐group (Table [1](#dom13698-tbl-0001){ref-type="table"}). Mean glycated haemoglobin (HbA1c) at baseline was similar across the strata of diabetes duration in both trials (8.4%‐8.8%), with the lowest values recorded in the \<5 years sub‐groups (Table [1](#dom13698-tbl-0001){ref-type="table"}). Increasing diabetes duration was associated with increasing age, higher prevalence of females, modestly higher systolic blood pressure and greater insulin use (Table [1](#dom13698-tbl-0001){ref-type="table"}). The prevalence of some macrovascular complications, including peripheral artery disease, ischaemic stroke, carotid artery stenosis and coronary artery bypass graft (CABG) surgery was higher with longer duration of diabetes; however, this was not observed for MI, heart failure and percutaneous coronary intervention (Table [1](#dom13698-tbl-0001){ref-type="table"}). Renal function (eGFR) at baseline worsened with increasing diabetes duration and, correspondingly, the prevalence of moderate or severe renal disease, including end‐stage renal disease, increased with longer duration of diabetes (Table [1](#dom13698-tbl-0001){ref-type="table"}).

###### 

Baseline characteristics according to duration of diabetes in the (A) LEADER and (B) SUSTAIN 6 trials

  ------------------------------------------------------------------------------------------------------------------------------
  Characteristic (A)                                  Duration of diabetes, years                                 
  --------------------------------------------------- ----------------------------- -------------- -------------- --------------
  Age, years, mean (SD)                               62.0 (7.1)                    63.7 (7.0)     65.5 (7.1)     68.1 (7.4)

  Male, n (%)                                         930 (67.5)                    3060 (65.2)    1564 (62.5)    436 (58.3)

  Female, n (%)                                       447 (32.5)                    1632 (34.8)    940 (37.5)     312 (41.7)

  HbA~1c~, %, mean (SD)                               8.4 (1.5)                     8.7 (1.5)      8.8 (1.5)      8.8 (1.5)

  Duration of diabetes, years, mean (SD)              2.7 (1.4)                     9.7 (2.7)      18.9 (2.7)     30.7 (5.7)

  CV history[a](#dom13698-note-0004){ref-type="fn"}                                                               

  Myocardial infarction, n (%)                        465 (33.8)                    1447 (30.8)    677 (27.0)     214 (28.6)

  Heart failure (NYHA II‐III), n (%)                  256 (18.6)                    663 (14.1)     296 (11.8)     87 (11.6)

  Percutaneous coronary intervention, n (%)           377 (27.4)                    1283 (27.3)    683 (27.3)     220 (29.4)

  Coronary artery bypass graft, n (%)                 183 (13.3)                    740 (15.8)     430 (17.2)     177 (23.7)

  Ischaemic stroke, n (%)                             150 (10.9)                    505 (10.8)     280 (11.2)     102 (13.6)

  Peripheral arterial disease, n (%)                  139 (10.1)                    546 (11.6)     356 (14.2)     123 (16.4)

  Carotid artery stenosis, n (%)                      86 (6.2)                      339 (7.2)      187 (7.5)      85 (11.4)

  \>50% stenosis of major artery, n (%)               331 (24.0)                    1179 (25.1)    650 (26.0)     212 (28.3)

  LV systolic dysfunction, n (%)                      176 (12.8)                    511 (10.9)     252 (10.1)     58 (7.8)

  LV diastolic dysfunction, n (%)                     263 (19.1)                    811 (17.3)     401 (16.0)     104 (13.9)

  Diabetes medication                                                                                             

  Oral antihyperglycaemic, n (%)                      1214 (88.2)                   4265 (90.9)    2153 (86.0)    595 (79.5)

  Metformin, n (%)                                    1055 (76.6)                   3731 (79.5)    1847 (73.8)    501 (67.0)

  SU, n (%)                                           596 (43.3)                    2601 (55.4)    1231 (49.2)    295 (39.4)

  Insulin, n (%)                                      269 (19.5)                    1900 (40.5)    1498 (59.8)    495 (66.2)

  Renal function                                                                                                  

  eGFR, mL/min/1.73 m^2^, mean (SD)                   86.0 (24.9)                   82.4 (26.7)    76.4 (28.4)    70.9 (27.7)

  Moderate or severe renal disease, n (%)             189 (13.7)                    957 (20.4)     732 (29.2)     272 (36.0)

  CV medication                                                                                                   

  ACEi, n (%)                                         722 (52.4)                    2429 (51.8)    1252 (50.0)    354 (47.3)

  ARB, n (%)                                          375 (27.2)                    1482 (31.6)    839 (33.5)     273 (36.5)

  Lipid‐lowering therapies, n (%)                     995 (72.3)                    3551 (75.7)    1924 (76.8)    596 (79.7)

  Anti‐platelet agents, n (%)                         905 (65.7)                    3131 (66.7)    1743 (69.6)    535 (71.5)

  Other risk factors                                                                                              

  Systolic BP, mm Hg, mean (SD)                       134.5 (16.9)                  135.5 (17.3)   137.1 (18.3)   137.1 (19.8)

  Diastolic BP, mm Hg, mean (SD)                      79.3 (10.0)                   77.7 (9.9)     75.8 (10.3)    73.7 (11.0)

  BMI, kg/m^2^, mean (SD)                             33.2 (6.4)\                   32.7 (6.2)\    32.1 (6.4)\    31.5 (6.1)\
                                                      n = 1376                      n = 4689       n = 2500       n = 747
  ------------------------------------------------------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic(B)                                                                Duration of diabetes, years                                 
  -------------------------------------------------------------------------------- ----------------------------- -------------- -------------- --------------
  Age, years, mean (SD)                                                            62.0 (7.7)                    63.9 (7.0)     65.8 (7.1)     68.3 (7.9)

  Male, n (%)                                                                      267 (63.3)                    971 (61.4)     587 (60.1)     177 (56.0)

  Female, n (%)                                                                    155 (36.7)                    611 (38.6)     390 (39.9)     139 (44.0)

  HbA1c, %, mean (SD)                                                              8.5 (1.5)                     8.7 (1.5)      8.7 (1.4)      8.8 (1.4)

  Duration of diabetes, years, mean (SD)                                           3.0 (1.5)                     10.2 (2.8)     19.1 (2.8)     30.7 (5.5)

  CV history[a](#dom13698-note-0004){ref-type="fn"}                                                                                            

  Myocardial infarction, n (%)                                                     165 (39.1)                    518 (32.7)     292 (29.9)     97 (30.7)

  Heart failure (NYHA II‐III), n (%)                                               105 (24.9)                    289 (18.3)     133 (13.6)     47 (14.9)

  Percutaneous coronary intervention, n (%)                                        155 (36.7)                    466 (29.5)     288 (29.5)     103 (32.6)

  Coronary artery bypass graft, n (%)                                              63 (14.9)                     249 (15.7)     180 (18.4)     85 (26.9)

  Ischaemic stroke, n (%)                                                          42 (10.0)                     191 (12.1)     107 (11.0)     43 (13.6)

  Peripheral arterial disease, n (%)                                               38 (9.0)                      206 (13.0)     150 (15.4)     59 (18.7)

  Carotid artery stenosis, n (%)                                                   35 (8.3)                      129 (8.2)      95 (9.7)       35 (11.1)

  \>50% stenosis of major artery, n (%)                                            165 (39.1)                    557 (35.2)     327 (33.5)     118 (37.3)

  LV systolic dysfunction, n (%)                                                   71 (16.8)                     192 (12.1)     108 (11.1)     31 (9.8)

  LV diastolic dysfunction, n (%)                                                  108 (25.6)                    342 (21.6)     170 (17.4)     50 (15.8)

  Diabetes medication                                                                                                                          

  Oral antihyperglycaemic, n (%)                                                   355 (84.1)                    1389 (87.8)    795 (81.4)     237 (75.0)

  Metformin, n (%)                                                                 311 (73.7)                    1228 (77.6)    688 (70.4)     190 (60.1)

  SU, n (%)                                                                        180 (42.7)                    737 (46.6)     386 (39.5)     107 (33.9)

  Insulin, n (%)                                                                   98 (23.2)                     676 (42.7)     568 (58.1)     209 (66.1)

  Renal function                                                                                                                               

  eGFR, mL/min/1.73 m^2^, mean (SD)                                                83.4 (25.3)                   79.0 (26.4)    71.9 (26.2)    65.0 (24.3)

  Moderate or severe renal disease,[b](#dom13698-note-0005){ref-type="fn"} n (%)   74 (17.5)                     389 (24.6)     330 (33.8)     146 (46.2)

  CV medication                                                                                                                                

  ACEi, n (%)                                                                      228 (54.0)                    811 (51.3)     459 (47.0)     144 (45.6)

  ARB, n (%)                                                                       104 (24.6)                    522 (33.0)     358 (36.6)     127 (40.2)

  Lipid‐lowering therapies, n (%)                                                  305 (72.3)                    1196 (75.6)    760 (77.8)     260 (82.3)

  Anti‐platelet agents, n (%)                                                      311 (73.7)                    1158 (73.2)    695 (71.1)     245 (77.5)

  Other risk factors                                                                                                                           

  Systolic BP, mm Hg, mean (SD)                                                    133.3 (15.9)                  135.4 (17.1)   136.4 (17.3)   137.5 (18.4)

  Diastolic BP, mm Hg, mean (SD)                                                   79.01 (9.8)                   77.7 (9.9)     76.1 (10.1)    74.1 (9.8)

  BMI, kg/m^2^, mean (SD)                                                          33.6 (6.4)                    33.2 (6.0)\    32.3 (6.5)\    31.6 (5.9)
                                                                                                                 n = 1578       n = 974        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; LV, left ventricular; NYHA, New York Heart Association; SD, standard deviation; SU, sulphonylurea.

Full analysis set, unless otherwise indicated. *P* values were derived using chi‐square test for differences between diabetes duration categories regardless of treatment group.

Based on medical history as reported by the trial investigator for each patient.

Includes end‐stage renal disease.

3.2. Risk of cardiorenal events according to diabetes duration regardless of treatment {#dom13698-sec-0005}
--------------------------------------------------------------------------------------

In the LEADER trial, MACE occurred more frequently with increasing diabetes duration (\<5 years: 167 patients \[12.1%\], 3.1 events/100 patient years of observation \[PYO\]; 5 to \<15 years: 631 patients \[13.4%\], 3.5 events/100 PYO; 15 to \<25 years: 383 patients \[15.3%\], 4.1 events/100 PYO; ≥25 years: 116 patients \[15.5%\], 4.1 events/100 PYO). Compared with patients with diabetes duration of \<5 years, HRs for MACE (95% confidence interval \[CI\]) were 1.13 (0.95; 1.34), 1.31 (1.09; 1.57) and 1.30 (1.03; 1.65) in patients with diabetes duration of 5 to \<15 years, 15 to \<25 years and ≥25 years, respectively. Similar results were obtained for the expanded MACE outcome (\<5 years: 273 patients \[19.8%\], 5.1 events/100 PYO; 5 to \<15 years: 981 patients \[20.9%\], 5.5 events/100 PYO; 15 to \<25 years: 566 patients \[22.6%\], 6.0 events/100 PYO; ≥25 years: 184 patients \[24.6%\], 6.5 events/100 PYO). Compared with patients with diabetes duration of \<5 years, HRs for expanded MACE (95% CI) were 1.06 (0.93; 1.21), 1.17 (1.02; 1.36) and 1.27 (1.05; 1.53) in patients with diabetes duration of 5 to \<15 years, 15 to \<25 years and ≥25 years, respectively. Incidence rates for cardiovascular death were 1.0, 1.3, 1.7 and 1.8 per 100 PYO, and were 1.0, 1.5, 2.2 and 2.6 per 100 PYO for nephropathy, according to increasing duration of diabetes.

In the SUSTAIN 6 trial, MACE occurred most frequently in the sub‐group of patients with the longest duration of diabetes, but the pattern of increasing risk of MACE with diabetes duration observed in the LEADER trial was less apparent (\<5 years: 35 patients \[8.3%\], 4.0 events/100 PYO; 5 to \<15 years: 109 patients \[6.9%\], 3.3 events/100 PYO; 15 to \<25 years: 77 patients \[7.9%\], 3.8 events/100 PYO; ≥25 years: 33 patients \[10.4%\], 5.1 events/100 PYO). Compared with patients with diabetes duration of \<5 years, HRs for MACE (95% CI) were 0.80 (0.55; 1.20), 0.83 (0.55; 1.27) and 1.03 (0.63; 1.70) in patients with diabetes duration of 5 to \<15 years, 15 to \<25 years and ≥25 years, respectively,. The frequency of expanded MACE did, however, increase with diabetes duration (\<5 years: 51 patients \[12.1%\], 5.9 events/100 PYO; 5 to \<15 years: 212 patients \[13.4%\], 6.5 events/100 PYO; 15 to \<25 years: 145 patients \[14.8%\], 7.2 events/100 PYO; ≥25 years: 55 patients \[17.4%\], 8.6 events/100 PYO). Compared with patients with diabetes duration of \<5 years, HRs (95% CI) for expanded MACE were 1.11 (0.82; 1.53), 1.15 (0.83; 1.61) and 1.29 (0.87; 1.91) in patients with diabetes duration of 5 to \<15 years, 15 to \<25 years and ≥25 years. Incidence rates for cardiovascular death were 1.4, 1.2, 1.3 and 2.0 per 100 PYO, and were 2.2, 1.8, 3.1 and 3.6 per 100 PYO for nephropathy, according to increasing duration of diabetes. Results were similar in the LEADER and SUSTAIN 6 trials in analyses adjusted for baseline covariates and in analyses using sub‐groups based on quartiles of diabetes duration (data not shown).

3.3. Cardiorenal efficacy of liraglutide and semaglutide according to diabetes duration {#dom13698-sec-0006}
---------------------------------------------------------------------------------------

Figure [1](#dom13698-fig-0001){ref-type="fig"} describes cardiorenal events in patients treated with liraglutide and semaglutide in the LEADER and SUSTAIN 6 trials, respectively, according to increasing duration of diabetes. Both GLP‐1 analogues exhibited consistent benefits on the primary MACE endpoint, and on expanded MACE, cardiovascular death and nephropathy across diabetes duration strata, with no evidence of statistical heterogeneity (P~interaction~ = not significant for all endpoints) (Figure [1](#dom13698-fig-0001){ref-type="fig"}). Similar results were obtained in analyses adjusted for baseline covariates (data not shown) and in analyses using sub‐groups based on quartiles of diabetes duration (Figure [S1](#dom13698-supitem-0001){ref-type="supplementary-material"}).

![Risk of cardiorenal events in patients treated with liraglutide (upper panel) or semaglutide (lower panel) vs placebo, by diabetes duration at baseline. LEADER total population: 9340. LEADER total population with diabetes duration available: 9321. SUSTAIN 6 total population (all patients with diabetes duration available): 3297. MACE comprised CV death, nonfatal MI and nonfatal stroke. Expanded MACE comprised MACE components plus coronary revascularization and hospitalization for unstable angina or heart failure. Nephropathy events were defined as new onset of macroalbuminuria or doubling of serum creatinine level and eGFR ≤45 mL/min/1.73 m^2^, the need for continuous renal‐replacement therapy or death from renal disease. Abbreviations: CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP‐1, glucagon‐like peptide‐1; MACE, major adverse cardiovascular events; N, number of patients with event; R, events per 100 patient years of observation](DOM-21-1745-g001){#dom13698-fig-0001}

4. DISCUSSION {#dom13698-sec-0007}
=============

The management of long‐standing type 2 diabetes remains an important challenge. In addition to the difficulties of maintaining glycaemic control, long duration of diabetes is associated with an increase in cardiovascular complications and progressive renal decline, which in turn contribute to heightened rates of morbidity and mortality in these patients.[1](#dom13698-bib-0001){ref-type="ref"}, [2](#dom13698-bib-0002){ref-type="ref"}, [3](#dom13698-bib-0003){ref-type="ref"}, [4](#dom13698-bib-0004){ref-type="ref"}, [5](#dom13698-bib-0005){ref-type="ref"} While much is known about the association of diabetes duration with rates of complications, considerably less is known about the details of the efficacy and safety of antihyperglycaemic agents, such as GLP‐1 analogues, as diabetes duration increases, particularly if GLP‐1 analogues have consistent cardiorenal efficacy across different durations of type 2 diabetes.

In an attempt to specifically address this subject, we conducted a post hoc analysis of two large cardiovascular outcome trials of liraglutide (LEADER)[7](#dom13698-bib-0007){ref-type="ref"} and semaglutide (SUSTAIN 6).[6](#dom13698-bib-0006){ref-type="ref"} Both trials demonstrated benefits of these GLP‐1 analogues compared with placebo on the primary outcome of MACE (HR \[95% CI\]: 0.87 \[0.78; 0.97\] with liraglutide in LEADER and 0.74 \[0.58; 0.95\] with semaglutide in SUSTAIN 6).[6](#dom13698-bib-0006){ref-type="ref"}, [7](#dom13698-bib-0007){ref-type="ref"} Furthermore, liraglutide was associated with a significant reduction in the risk of cardiovascular death (HR \[95% CI\]: 0.78 \[0.66; 0.93\]),[7](#dom13698-bib-0007){ref-type="ref"} with consistent benefits observed in patients with atherosclerotic vascular disease, with or without a prior ischaemic event.[8](#dom13698-bib-0008){ref-type="ref"}, [9](#dom13698-bib-0009){ref-type="ref"} Several mechanisms, including anti‐inflammatory and anti‐atherosclerotic effects,[10](#dom13698-bib-0010){ref-type="ref"}, [11](#dom13698-bib-0011){ref-type="ref"}, [12](#dom13698-bib-0012){ref-type="ref"} have been suggested to mediate the cardiovascular benefits of GLP‐1 analogues that are observed in addition to those of conventional risk reduction therapies including lipid lowering.[13](#dom13698-bib-0013){ref-type="ref"}

Our post hoc analyses of the LEADER and SUSTAIN 6 trials confirm that increasing duration of diabetes is associated with increased rates of cardiorenal outcomes. At baseline, increasing duration of diabetes was associated with a greater prevalence of peripheral artery disease, ischaemic stroke, history of CABG and renal disease. During the trials, there was a trend for higher rates of MACE, expanded MACE, cardiovascular death and nephropathy with longer duration of type 2 diabetes. Importantly, both liraglutide and semaglutide exhibited consistent benefits on these cardiorenal endpoints irrespective of the duration of diabetes. For liraglutide, this finding of consistent benefits in apparently higher‐ and lower‐risk patients is not concordant with the pre‐specified sub‐group analysis of the LEADER trial, which showed a significant interaction in favour of patients with established CVD.[7](#dom13698-bib-0007){ref-type="ref"} A more recent post hoc analysis of the LEADER trial showed that liraglutide reduced CV events both in patients with a history of MI or stroke and in those with established atherosclerotic cardiovascular disease without MI or stroke, indicating that the CV benefits of liraglutide are maintained across a clinically relevant continuum of risk in type 2 diabetes with atherosclerosis or prior ischaemic events.[9](#dom13698-bib-0009){ref-type="ref"} However, in the current analysis, patients with a shorter duration of diabetes had a higher prevalence of heart failure, myocardial infarction, and systolic or diastolic dysfunction at baseline, compared with those with a longer duration of diabetes, indicating previous events. Hence, it is difficult to make a direct comparison with the previously reported results.

The similar designs of the LEADER and SUSTAIN 6 trials facilitate comparison of our findings across the two trials, but this may also limit our findings to the patients enrolled in these trials. While not all glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have demonstrated cardiorenal efficacy, it could be of interest for future analyses to examine the impact of diabetes duration on the cardiorenal effects of GLP‐1RAs across a wider range of trials and patients.

In summary, our analyses provide reassurance that the cardiorenal efficacy and safety of liraglutide and semaglutide are maintained over a broad range of patients, from those who are relatively newly diagnosed to those with long‐standing type 2 diabetes.
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###### 

**Figure S1.** Risk of cardiorenal events in patients treated with liraglutide (upper panel) or semaglutide (lower panel) versus placebo, by diabetes duration quartiles at baseline.

###### 

Click here for additional data file.
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